These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1781974)

  • 1. Neuropsychological assessment in clinical trials of Alzheimer disease.
    Claman DL; Radebaugh TS
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S49-56. PubMed ID: 1781974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scales as outcome measures for Alzheimer's disease.
    Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
    Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial design issues in mild to moderate Alzheimer disease.
    Knopman DS
    Cogn Behav Neurol; 2008 Dec; 21(4):197-201. PubMed ID: 19057167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome methodologies for pharmacologic trials in mild, moderate, and severe Alzheimer's disease. Proceedings of a meeting. New York, New York, July 26, 1994.
    Int Psychogeriatr; 1996; 8(2):155-344. PubMed ID: 9091069
    [No Abstract]   [Full Text] [Related]  

  • 6. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
    McLendon BM; Doraiswamy PM
    J Geriatr Psychiatry Neurol; 1999; 12(1):39-48. PubMed ID: 10447153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Feldman H; Anand R; Blesa R; Dubois B; Gray J; Homma A; Mohr E; Morris JC; Parys W; Raschig A; Robillard A
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():61-4. PubMed ID: 9305520
    [No Abstract]   [Full Text] [Related]  

  • 10. Cognitive models of physicians' legal standard and personal judgments of competency in patients with Alzheimer's disease.
    Earnst KS; Marson DC; Harrell LE
    J Am Geriatr Soc; 2000 Aug; 48(8):919-27. PubMed ID: 10968295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials in dementia: learning effects with repeated testing.
    Claus JJ; Mohr E; Chase TN
    J Psychiatry Neurosci; 1991 Mar; 16(1):1-4. PubMed ID: 2049365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease.
    Cummings JL
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S1-9. PubMed ID: 9339266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cognitive testing in disease modifying AD trials.
    Visser PJ
    J Nutr Health Aging; 2006; 10(2):131-2; discussion 132-3. PubMed ID: 16554947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Reisberg B; Schneider L; Doody R; Anand R; Feldman H; Haraguchi H; Kumar R; Lucca U; Mangone CA; Mohr E; Morris JC; Rogers S; Sawada T
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():8-18. PubMed ID: 9305508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
    Bernick C; Cummings J; Raman R; Sun X; Aisen P
    Arch Neurol; 2012 Jul; 69(7):901-5. PubMed ID: 22431834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials.
    Rockwood K; MacKnight C
    Neuroepidemiology; 2001 May; 20(2):51-6. PubMed ID: 11359070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?
    Snyder PJ; Kahle-Wrobleski K; Brannan S; Miller DS; Schindler RJ; DeSanti S; Ryan JM; Morrison G; Grundman M; Chandler J; Caselli RJ; Isaac M; Bain L; Carrillo MC
    Alzheimers Dement; 2014 Nov; 10(6):853-60. PubMed ID: 25458309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychological and functional measures of severity in Alzheimer disease, frontotemporal dementia, and semantic dementia.
    Rosen HJ; Narvaez JM; Hallam B; Kramer JH; Wyss-Coray C; Gearhart R; Johnson JK; Miller BL
    Alzheimer Dis Assoc Disord; 2004; 18(4):202-7. PubMed ID: 15592131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.